CME: Do You Know Your ADCs in Triple-Negative Breast Cancer? Medical Education on ReachMD

Overview
Antibody-drug conjugates (ADCs) represent one of the fastest-growing classes of drugs in oncology. ADCs aim to improve the therapeutic index of anticancer therapies by restricting the systemic delivery—such as that associated with chemotherapy, which affects healthy cells—to cells that express the target antigen of the selected monoclonal antibody. Potentially practice-changing innovations in ADC design, biomarker development, and combinations are ongoing in both preclinical and clinical studies. It is essential for clinicians to understand the interactions between ADCs and tumors and on- and off-target toxicities in order to realize the true potential of this class of drugs in the treatment of cancer and ultimately improve outcomes for patients. In triple-negative breast cancer (TNBC), healthcare providers should understand how current and emerging ADCs address unmet needs for patients with pretreated metastatic disease (i.e., after treatment that may include checkpoint inhibitors). There is also a need to address other key issues, such as proactive toxicity management, as well as next steps in research that may yield additional meaningful improvements in patient outcomes through the use of ADCs in combination with other treatments or in earlier lines of therapy for TNBC. Lastly, there is a need to explore the presence of disparities in access, care, and treatment of African American (AA) women diagnosed with TNBC.
Target Audience
This activity has been designed to meet the educational needs of multidisciplinary teams, including oncologists, nurses, pharmacists, and other clinicians involved in the management of patients with TNBC.
Learning Objectives
After participating in this educational activity, participants should be better able to:
1. Recognize the profiles of patients with TNBC who may benefit from treatment with antibody-drug conjugates
2. Recognize and manage treatment-related adverse events associated with the use of ADCs
3. Discuss the latest clinical evidence with emerging ADCs, combinations, and future role of ADCs in the treatment of patients with TNBC
4. Increase awareness of barriers to access, care, and treatment that exist in the care of women diagnosed with TNBC
Accreditation and Credit Designation Statements

In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.25 hours of Nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.25 contact hours/0.125 CEUs of Pharmacy contact hours.
The Universal Activity Number for this program is UAN JA0006235-0000-22-016-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Faculty Disclosure of Commercial Relationships
In accordance with the ACCME Standards for Integrity and Independence and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies (commercial interest) within the last 24-months. The ACCME requires us to disqualify individuals who refuse to provide this information from involvement in the planning and implementation of accredited continuing education. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence.

The following faculty have reported relationships with ineligible companies that have been mitigated:

Aditya Bardia, MD, MPH, faculty for this educational event, is on contract research for Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics/Gilead, Daiichi Pharma/Astra Zeneca, and Eli Lilly; and receives consulting fees from Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics/Gilead, Sanofi, Daiichi Pharma/Astra Zeneca, Phillips, Eli Lilly, and Foundation Medicine.

Sara A. Hurvitz, MD, FACP, faculty for this educational event, is on contracted research for Ambrx, Amgen, Astra Zeneca, Arvinas, Bayer, Cytomx, Daiichi-Sankyo, Dignitana, Genentech/Roche, Gilead, GSK, Immunomedics, Eli Lilly, Macrogenics, Novartis, Pfizer, OBI Pharma, Orinove, Pieris, PUMA, Radius, Sanofi, Zymeworks, Phoenix Molecular Designs, Ltd, Samumed, SeaGen, Lilly, Sanofi, 4DPharma, Artios, Dantari, NK Max, Pieris, Pyxis, Biotheranostics.

Kevin Kalinsky, MD, MS, faculty for this program receives consulting fees from Eli Lilly, Pfizer, Novartis, AstraZeneca, Daiichi Sankyo, 4D Pharma, Oncosec, Immunomedics, Puma, Merck, Seattle Genetics, Mersara, and Gyclocel and spouse receives consulting fees from Earx.

All the relevant financial relationships for these individuals have been mitigated.
Planners and Managers Disclosure List
The following reviewers/planners have reported no relationships with ineligible companies that have been mitigated:

Robert Garris, PharmD, MPH, planner for this educational event, has no relevant financial relationships with ineligible companies.

William Mencia, MD, FACEHP, CHCP, planner for this educational event, has no relevant financial relationships with ineligible companies.

All the relevant financial relationships for these individuals have been mitigated.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
Acknowledgment
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.
Fee Statement
This activity is FREE to all participants.
Instructions for Completion
During the period 6/15/2022 through 6/30/2023, registered participants wishing to receive continuing education credit for this activity must follow these steps:
1. Read the learning objectives and faculty disclosures.
2. Answer a pre-program question.
3. View the program.
4. Complete the post-test with a score of 100%.
5. Complete activity evaluation.
6. Apply for credit and either bank your credits or print your certificate.
For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.
System Requirements
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
Publication Dates
Release Date: 06/15/2022
Expiration Date: 06/30/2023